5-Amino-1MQ half-life & pharmacokinetics

Reported half-life

Plasma half-life in rodent models approximately 2-4 hours after oral administration; ~1-2 hours after intraperitoneal administration. Limited published pharmacokinetic data in larger species. Oral bioavailability is reasonable due to small molecular size (~160 Da) and water solubility of the quinolinium cation, supporting oral dosing protocols in research models.

The half-life and pharmacokinetic profile of 5-Amino-1MQ reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Oral gavage (rodent research; standard route)
• Intraperitoneal injection (research)
• Subcutaneous injection (research, less common)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT); methyl-donor and NAD+ pathway modulator.

Mechanism context

Half-life interpretation depends on the underlying mechanism. 5-Amino-1MQ acts as follows:

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule quinolinium-based selective inhibitor of nicotinamide N-methyltransferase (NNMT, EC 2.1.1.1), an enzyme that catalyses the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH). NNMT therefore consumes two critical cellular cofactors: SAM (the principal cellular methyl donor) and nicotinamide (a precursor for NAD+ salvage biosynthesis). Pathological overexpression of NNMT — well documented in white adipose tissue of obese mice and humans, and in several cancers — produces a 'double depletion' phenotype: reduced SAM availability for methylation reactions (DNA methylation, histone methylation, phospholipid methylation, neurotransmitter synthesis) and reduced nicotinamide pool feeding the NAD+ salvage pathway. The resulting low NAD+ state impairs sirtuin function, PARP signalling, and mitochondrial bioenergetics — producing the metabolic phenotype characteristic of NNMT-overexpressing tissues.

See the full 5-Amino-1MQ research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.